Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
by
Jamalian, Samira
, Jin, Jin Y.
, Dolton, Michael
, Franco, Yesenia
, Quartino, Angelica
, Ramakrishnan, Vidya
, Hsu, Joy C.
, Wildsmith, Kristin
, Manser, Paul
, Teng, Edmond
, Chanu, Pascal
in
Activities of daily living
/ Alzheimer Disease - diagnostic imaging
/ Alzheimer Disease - drug therapy
/ Alzheimer's disease
/ Clinical trials
/ Cognitive ability
/ Dementia
/ Disease Progression
/ Humans
/ Medical imaging
/ Mental Status and Dementia Tests
/ Neuroimaging
/ Prescription drugs
/ Prospective Studies
/ Research Design
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
by
Jamalian, Samira
, Jin, Jin Y.
, Dolton, Michael
, Franco, Yesenia
, Quartino, Angelica
, Ramakrishnan, Vidya
, Hsu, Joy C.
, Wildsmith, Kristin
, Manser, Paul
, Teng, Edmond
, Chanu, Pascal
in
Activities of daily living
/ Alzheimer Disease - diagnostic imaging
/ Alzheimer Disease - drug therapy
/ Alzheimer's disease
/ Clinical trials
/ Cognitive ability
/ Dementia
/ Disease Progression
/ Humans
/ Medical imaging
/ Mental Status and Dementia Tests
/ Neuroimaging
/ Prescription drugs
/ Prospective Studies
/ Research Design
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
by
Jamalian, Samira
, Jin, Jin Y.
, Dolton, Michael
, Franco, Yesenia
, Quartino, Angelica
, Ramakrishnan, Vidya
, Hsu, Joy C.
, Wildsmith, Kristin
, Manser, Paul
, Teng, Edmond
, Chanu, Pascal
in
Activities of daily living
/ Alzheimer Disease - diagnostic imaging
/ Alzheimer Disease - drug therapy
/ Alzheimer's disease
/ Clinical trials
/ Cognitive ability
/ Dementia
/ Disease Progression
/ Humans
/ Medical imaging
/ Mental Status and Dementia Tests
/ Neuroimaging
/ Prescription drugs
/ Prospective Studies
/ Research Design
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
Journal Article
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
2023
Request Book From Autostore
and Choose the Collection Method
Overview
There is strong interest in developing predictive models to better understand individual heterogeneity and disease progression in Alzheimer's disease (AD). We have built upon previous longitudinal AD progression models, using a nonlinear, mixed‐effect modeling approach to predict Clinical Dementia Rating Scale – Sum of Boxes (CDR‐SB) progression. Data from the Alzheimer's Disease Neuroimaging Initiative (observational study) and placebo arms from four interventional trials (N = 1093) were used for model building. The placebo arms from two additional interventional trials (N = 805) were used for external model validation. In this modeling framework, CDR‐SB progression over the disease trajectory timescale was obtained for each participant by estimating disease onset time (DOT). Disease progression following DOT was described by both global progression rate (RATE) and individual progression rate (α). Baseline Mini‐Mental State Examination and CDR‐SB scores described the interindividual variabilities in DOT and α well. This model successfully predicted outcomes in the external validation datasets, supporting its suitability for prospective prediction and use in design of future trials. By predicting individual participants' disease progression trajectories using baseline characteristics and comparing these against the observed responses to new agents, the model can help assess treatment effects and support decision making for future trials.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
This website uses cookies to ensure you get the best experience on our website.